Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. It can be used for severe eosinophilic asthma.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | 6-8 weeks | $ 2013 | |
2 mg | 6-8 weeks | $ 3422 | |
4 mg | 6-8 weeks | $ 5796 | |
10 mg | 6-8 weeks | $ 10545 | |
20 mg | 6-8 weeks | $ 16450 |
Description | Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. It can be used for severe eosinophilic asthma. |
Synonyms | MEDI-563, BIW-8405 |
CAS No. | 1044511-01-4 |
Molecular Weight | N/A |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom